To establish whether Rac1 might mediate SPARC effects on melanoma cell plasticity, we made use of a constitutively active Rac1 mutant (RacQL) and a dominant negative Rac1 mutant (RacDN) to modulate Rac1 activity. The gene discussed is SPARC; the disease is melanoma.